Epclusa:A Novel Treatment Drug for Hepatitis C
- VernacularTitle:新型丙肝治疗药物Epclusa概述
- Author:
Jiao WANG
;
Guangzhong LIU
- Keywords:
HCV;
Epclusa;
Sofosbuvir;
Velpatasvir;
Clinical trials
- From:
China Pharmacist
2017;20(3):543-547
- CountryChina
- Language:Chinese
-
Abstract:
Velpatasvir is a new generation of NS5A inhibitors, and combined with marketed sofosbuvir, compound tablets Epclusa was obtained and approved by FDA in June, 2016, which is used for the treatment of adult patients infected with chronic hepatitis C vi-rus ( HCV) with all genotypes. The mechanism of action, pharmacodynamics, pharmacokinetics, clinical trials and safety of Epclusa were reviewed in this article.
